NCE-1 Intelligence & Market Opportunity

Lumakras

Sotorasib

Anticancer

Oral Tablet

Approval Date

28-May-21

NCE-1 Date

28-May-25

NCE Date

28-May-26

Commercial snapshot

Market performance & projections

Revenue ($M)

363

CAGR (%)

0.0977

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

429

2027

470

2028

499

2029

527

2030

554

2031

574

2032

593

Molecule profile

Details & specifications

Molecule

Sotorasib

Innovator

AMGEN INC

Dosage Form

Oral Tablet

Strength

320 mg, 240 mg, 120 mg

Therapeutic Category

Anticancer

Usage

To treat types of non-small cell lung cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.